Emmanuel Antonarakis, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Tokai
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Novartis
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Medivation
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Johnson & Johnson
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    GlaxoSmithKline
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Genentech
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Lilly
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Celgene
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Bristol Myers-Squibb
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Bayer
    Date added:
    Date updated:
    11/09/2023

Pages

Return to PARP Inhibitors: Assessing the Clinical Trial Landscape Webcast (2021)